Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma  by Johnston, Laura J. et al.
555B B & M T
INTRODUCTION
High-dose chemotherapy and autologous hematopoietic
cell transplantation (HDT/AHCT), compared with standard
salvage therapy, is known to improve progression-free sur-
vival (PFS) and overall survival (OS) in chemosensitive,
relapsed diffuse large cell lymphoma [1]. In the Parma Study,
HDT/AHCT was restricted to initial complete responders
and the 50% of patients who responded to salvage chemo-
therapy. Among this select group of chemosensitive patients,
36% became event-free survivors at 8 years. In an attempt to
improve the survival of patients with poor-risk non-Hodgkin’s
lymphoma (NHL), Gianni et al. [2] conducted a randomized
trial of high-dose sequential chemotherapy (HDSC) and
AHCT versus standard therapy in untreated patients with B-cell,
intermediate-grade lymphoma. Complete remission (CR)
rate, PFS, and event-free survival (EFS) were signiﬁcantly
increased after HDSC/AHCT compared with standard ther-
apy. These results in the newly diagnosed NHL population
encouraged us to apply the identical HDSC regimen to
high-risk or relapsed/refractory NHL patients with the goal
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ABSTRACT
We conducted a pilot study in 20 patients with high-risk or recurrent/refractory non-Hodgkin’s lymphoma (NHL)
using high-dose sequential chemotherapy (HDSC) and autologous hematopoietic cell transplantation (AHCT).
After cytoreduction with standard salvage therapy, HDSC/AHCT was administered in 4 phases at 2- to 4-week
intervals. Phase 1 consisted of cyclophosphamide 7 g/m2 followed by granulocyte colony-stimulating factor (G-CSF)
at 10 µg/kg per day and leukapheresis upon recovery from white blood cell nadir. The hematopoietic cell product
was enriched by Percoll gradient separation and purged with a B-cell or T-cell monoclonal antibody panel and com-
plement. Phase 2 consisted of methotrexate 8 g/m2 with leucovorin rescue and vincristine 1.4 mg/m2. Phase 3 was
etoposide 2 g/m2 with G-CSF 5 µg/kg per day. In phase 4, the preparative regimen of mitoxantrone 60 mg/m2 and
melphalan 180 mg/m2 was administered followed by AHCT. The NHL histologies were diffuse large cell, follicu-
lar/diffuse mixed, small noncleaved cell, T-cell–rich B-cell, lymphoblastic, and peripheral T cell. The remission sta-
tus was first partial remission (PR1; n = 1) or beyond first complete remission (post-CR1; n = 19). Of the 20 patients
enrolled, 11 proceeded through all 4 phases. Nine were removed from the study after the first or second phase
because of progressive disease (n = 5), poor hematopoietic cell mobilization (n = 1), excessive toxicity (n = 2), and
chronic active hepatitis C (n = 1). Treatment-related toxicities in the remaining 11 transplant recipients were car-
diomyopathy, hemorrhagic cystitis, persistent cytopenias, acute renal failure, abnormal liver function test results,
and infectious complications. There were no treatment-related deaths. Eight of the 11 transplant recipients were
alive, 6 without disease, at a median follow-up of 2.7 years. The estimated median 2-year event-free survival was
55%, and overall survival was 70%. We conclude that HDSC/AHCT in refractory/recurrent NHL is associated with
considerable acute and chronic toxicities. Given the toxicity profile, efficacy data were not sufficiently promising to
warrant further study.
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of improving CR rate, PFS, and OS beyond the current
expectations from the conventional HDT/AHCT approach.
Over a 21-month period, we enrolled 20 patients with high-
risk or relapsed/ refractory NHL. Unfortunately, treatment-
related toxicities as well as progressive disease prevented
nearly half of the originally enrolled patients from complet-
ing all phases of HDSC, thereby demonstrating that this
HDSC/AHCT regimen did not confer an advantage over
standard salvage chemotherapy with subsequent
HDT/AHCT.
MATERIALS AND METHODS
Patient Eligibility
Between February 1996 and November 1997, 19 patients
with relapsed or refractory NHL and 1 patient with previ-
ously untreated, poor-risk disease were enrolled in the
HDSC/AHCT protocol. NHL patients were eligible if they
had failed to achieve CR with standard induction or salvage
chemotherapy (induction failure [IF]), if they had relapsed
after attaining CR, or if they had newly diagnosed diffuse
large cell or mixed lymphoma with high-risk features. High
risk was deﬁned as having 2 or more of the following fea-
tures at diagnosis: elevated serum lactate dehydrogenase
(LDH), Ann Arbor stage III or IV [3], or Eastern Coopera-
tive Oncology Group performance status 2 to 4 [4]. Patients
with active central nervous system disease were excluded.
Other criteria for eligibility included normal cardiac, pul-
monary, hepatic, and renal function based on nuclear
angiography, pulmonary function tests, and clinical and lab-
oratory examinations. All tissue specimens were reviewed at
Stanford University. The study protocol was approved by
the Institutional Review Board at Stanford University, and
all patients gave written informed consent.
Study Definitions
Patients without clinical or radiological evidence of dis-
ease or bone marrow involvement were deﬁned as being in
CR; patients with measurable residual disease were deﬁned
as being in partial remission (PR). Chemosensitive disease
was defined as response to standard cytoreductive chemo-
therapy. Patients who did not achieve CR with standard
chemotherapy were considered to be in IF. Relapse was
deﬁned as biopsy-proven disease in a new site or growth of
disease in any previously involved sites. Early treatment-
related mortality (TRM) included death from any cause
except relapse occurring within 100 days after transplanta-
tion. All survival and relapse statistics were analyzed from
the beginning of phase 1 therapy. EFS was calculated using
death from any cause and relapse as events. Relapse rate was
calculated using relapse as an event.
Treatment Regimen
HDSC was administered in 4 phases (Figure 1). The ﬁrst
phase was cyclophosphamide, 1.4 g/m2, over 1 hour every
3 hours for 5 doses (total dose, 7 gm/m2) and granulocyte
colony-stimulating factor (G-CSF), 10 µg/kg per day, begin-
ning 24 hours after completion of the cyclophosphamide
infusion. Forced diuresis and hyperhydration accom-
panied the cyclophosphamide infusion and continued for
24 hours after completion of the infusion. Because 4 of
the initial 13 patients experienced hemorrhagic cystitis,
the final 7 patients received continuous bladder irrigation
with a sorbitol solution from the beginning of cyclophos-
phamide infusion until 24 hours after completion of the
infusion. Leukapheresis was begun upon recovery of white
blood cell count (WBC) (>1000/µL). Phase 2 was vincristine,
1.4 mg/m2 (maximum 2 mg), and methotrexate, 8 g/m2, with
leucovorin rescue. Methotrexate was administered over
6 hours, 30 minutes after the vincristine. Leucovorin was
begun 24 hours after the start of the methotrexate infusion
and discontinued when the methotrexate level reached
<0.02 µmol/L. Phase 3 was etoposide, 2 g/m2, infused over
10 to 12 hours at 200 mg/m2 per hour. G-CSF, 5 µg/kg per
day, was begun 72 hours after etoposide completion and con-
tinued until the absolute neutrophil count (ANC) was
>1000/µL for 3 consecutive days. Phase 4 was the preparative
regimen of mitoxantrone, 60 mg/m2, and melphalan, 180
mg/m2, followed by AHCT. On day –4, 3 doses of mitox-
antrone (20 mg/m2 each) were administered over 1 hour
every 2 hours followed by 2 days of rest. On day –1, 3 doses
of melphalan (60 mg/m2) were administered over 1 hour
every 2 hours. On day 0, the autologous hematopoietic cells
were rapidly thawed in a 37°C water bath and infused by
gravity at the bedside. G-CSF infusion was begun at 10 µg/kg
per day on day 1 until the ANC exceeded 1000/µL for 3 con-
secutive days.
Chemotherapy doses were based on adjusted ideal body
weight or actual body weight in phases 1 and 4 and actual
body weight only in phases 2 and 3. Adjusted ideal body
weight was used if the actual weight was 15 kg or more
above the ideal weight. The adjusted ideal body weight was
calculated by adding 50% of the difference between the
actual body weight and the ideal body weight to the ideal
body weight [adjusted ideal body weight = ideal + 0.5(actual
– ideal)]. The ideal body weight was calculated using
Devine’s formulas [5]. The phases were administered in 2-
to 4-week intervals. Patients with evidence of progressive
disease before the initiation of the next phase of therapy
were removed from the study.
Patients with bone marrow involvement of large cells,
epidural disease, sinus or testicular involvement received
intrathecal methotrexate, 12 mg every week for 4 weeks.
Radiation therapy was administered to areas of prior bulky
disease (deﬁned as tumor masses >5 cm in any dimension)
and the areas of residual disease after engraftment (ANC
Figure 1. Schema of high-dose sequential chemotherapy and autolo-
gous hematopoietic cell transplantation.
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>1000/µL and platelet count >50,000/µL), beginning 30 to
100 days after transplantation. All previously involved or
residual sites of disease received a dose of 1980 to 2000 cGy
over 10 to 17 days.
Collection and Purging of Hematopoietic Precursor
Cells
Autologous hematopoietic cells were collected from the
peripheral blood via a central venous catheter upon WBC
recovery after phase 1 (cyclophosphamide and G-CSF).
Leukapheresis continued on 3 to 4 hours of daily apheresis
collections until a total of 1 × 109/kg mononuclear cells was
collected. The product was applied to a discontinuous Percoll
gradient. The low-density fractions were then treated with
anti–B-cell (CD9, CD10, CD19, CD20) or anti–T-cell (CD2,
CD3, CD4, CD5, CD6, CD8, D28) antibodies and comple-
ment and frozen in dimethylsulfoxide and autologous serum
[6]. For backup purposes, additional aphereses were per-
formed and the products frozen without further manipulation.
Supportive Care and Follow-Up
Patients were admitted to the Stanford Compromised
Host Unit for all phases of the regimen. During hospital
admissions, patients were housed in private rooms with high-
efficiency particulate air filtration systems. Patients were
discharged 24 hours after completion of phase 1 or 3 chemo-
therapy and the day after AHCT. After phase 2 (high-dose
methotrexate), patients remained in the hospital until docu-
mentation of a methotrexate level <0.02 µmol/L. After
phases 1 and 4, patients received oral ciproﬂoxacin, rifampin,
ﬂuconazole, and subcutaneous G-CSF until ANC recovery
(>1000/µL). At the initiation of phase 4, patients received
oral ciproﬂoxacin for gut decontamination and Pneumocystis
carinii prophylaxis with trimethoprim/sulfamethoxazole for
4 days and reinstitution on day 30 through 60. Patients aller-
gic to sulfa drugs received monthly inhaled pentamidine
treatments. Vancomycin was started when a patient became
neutropenic, and broad-spectrum antibiotics were started
from the ﬁrst febrile episode. Amphotericin was begun for
patients with persistent fevers while on broad-spectrum
antibiotics. All blood products were irradiated to 2500 cGy,
and cytomegalovirus (CMV)-negative blood products were
used for patients who were CMV seronegative. Platelets were
transfused to maintain a platelet count above 10,000/µL, and
red blood cells (RBCs) were transfused to maintain a hemat-
ocrit >30%. As veno-occlusive disease prevention, patients
receiving phase 4 chemotherapy received continuous-infusion
heparin at 100 U/kg per day until neutrophil engraftment.
Bone marrow biopsies and aspirates were obtained rou-
tinely to assess engraftment, cytogenetic abnormalities, and
lymphomatous involvement on days 60, 100, and 180 and
Table 1. Characteristics of Patients Enrolled in the High-Dose Sequential
Chemotherapy and Autologous Hematopoietic Cell Transplantation
(HDSC/AHCT) Regimen*
HDSC/AHCT
Initial Group Group
n 20 11
Age, y 49 (21-60) 47 (33-60)
Sex, M/F 14/6 9/2
Histologic subtype
Diffuse large cell 13 8
Follicular, diffuse mixed 2 0
Small noncleaved 2 2
T-cell–rich B cell 1 1
Lymphoblastic 1 0
Peripheral T cell 1 0
Remission status
Responsive high-risk 1 1
Second complete remission 3 1
Responsive relapse 7 5
PR1 2 2
PR2 4 2
PR3 1 1
Untested first relapse 2 2
Induction failure 7 2
IF1 3 0
IF2 4 2
*Data are n or median (range). PR indicates partial remission; IF,
induction failure.
Figure 2. Patient ﬂow of all patients with high-risk or recurrent/refractory non-Hodgkin’s lymphoma initially enrolled on high-dose sequential
chemotherapy and autologous hematopoietic cell transplantation from the time of enrollment to transplantation.
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annually after transplantation. Restaging radiologic studies
were obtained 3 to 6 months after transplantation and annu-
ally as indicated. Physical examinations occurred every 2 to 6
months with radiologic and laboratory studies as indicated.
Statistics
Two separate survival analyses were conducted, 1 inten-
tion-to-treat and 1 of transplant recipients only. OS, EFS,
and relapse rate curves were calculated by Kaplan-Meier
method [7].
RESULTS
Patient Flow and Characteristics
The characteristics of the patients enrolled in the
HDSC/AHCT regimen, including histology and remission
status, are summarized in Table 1. Of the 20 patients
enrolled, 11 completed all 4 phases and received AHCT.
Nine were removed from the study after the ﬁrst or second
phase of the protocol due to progressive disease (n = 5), poor
mobilization (n = 1), persistent hemorrhagic cystitis accompa-
nied by fevers during neutropenia (n = 1), prolonged fevers
during and after resolution of neutropenia (n = 1), or chronic
active hepatitis C (n = 1) (Figure 2). Nine of the 11 transplant
recipients were treated with CHOP (cyclophosphamide, vin-
cristine, doxorubicin, and prednisone) therapy as ﬁrst induc-
tion (2 to 8 cycles; median, 6 cycles). One patient had an ini-
tial diagnosis of lymphocyte-predominant Hodgkin’s disease
and received ABVD (adriamycin, bleomycin, vinblastine,
dacarbazine) as induction before transformation to
T-cell–rich B-cell NHL. The final patient received M-
BACOD (methotrexate, leucovorin, bleomycin, adriamycin,
cyclophosphamide, vincristine, dexamethasone) as ﬁrst induc-
tion therapy. Seven of the 11 patients who had undergone
transplantation had received a total of 2 different chemo-
therapy regimens before HDT and AHCT; all second regi-
mens were platinum-containing (DHAP [dexamethasone,
cytarabine, cisplatin] or ESHAP [etoposide, solumedrol,
cytarabine, cisplatin]). Two patients received transplants in
first relapse without receiving salvage therapy before
HDSC/AHCT. One of them had received involved-ﬁeld irra-
diation as a component of initial induction therapy. Similar to
the patients completing all phases of HDSC and AHCT, the
majority of patients removed from the study received CHOP
therapy as initial induction (7 of 9) and a platinum-containing
regimen as salvage (6 of 9). Six of the 9 ineligible patients had
received a total of 2 prior chemotherapy regimens, whereas
1 each had received no chemotherapy (splenectomy alone),
3 regimens, and 4 regimens before enrollment.
Nine of the 11 patients receiving all 4 phases of HDSC
and AHCT had sufficient pretransplantation clinical data
available to determine their age-adjusted International
Prognostic Index (IPI) [4]. Three of the 9 patients were in a
high-/intermediate- or high-risk IPI group, whereas 6 of
9 ineligible patients were high/intermediate or high risk at
the time of enrollment.
Intrathecal methotrexate was administered to 5 of the
11 transplantation patients during either initial induction or
Table 2. Toxicities Identiﬁed During the High-Dose Sequential Chemo-
therapy Regimen in Evaluable Patients (n = 11)
Infections 6
Central-line sepsis 1
Pulmonary aspergillosis 1
Cutaneous herpes simplex virus I 2
Dermatomal Varicella zoster virus 2
Hemorrhagic cystitis 3
Cardiomyopathy 2
Cytopenias/myelodysplasia 2
Acute renal failure 1
Liver function test abnormalities 2
Mucositis (grade II) 3
Treatment-related mortality 0
Figure 3. Outcome of all patients with high-risk or recurrent/refractory non-Hodgkin’s lymphoma initially enrolled on high-dose sequential
chemotherapy and autologous hematopoietic cell transplantation (HCT). TRM indicates treatment-related mortality.
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salvage therapy. Three of the 11 transplantation patients began
consolidative radiotherapy after transplantation. Two of the 3
were unable to complete the radiation course, 1 because of
thrombocytopenia and the other because of cardiomyopathy.
Hematologic Data
The 11 patients proceeding to AHCT required a
median of 2 apheresis collections (range, 1-6 collections) to
achieve the target number of mononuclear cells. The
Figure 4. Kaplan-Meier survival curves of all patients with high-risk or recurrent/refractory non-Hodgkin’s lymphoma initially enrolled on high-
dose sequential chemotherapy and autologous hematopoietic cell transplantation (n = 20). indicates overall survival; , event-free sur-
vival; , relapse rate.
Figure 5. Kaplan-Meier survival curves of patients with high-risk or recurrent/refractory non-Hodgkin’s lymphoma completing all 4 phases of
high-dose sequential chemotherapy and autologous hematopoietic cell transplantation (n = 11). indicates overall survival; , event-free
survival; , relapse rate.
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median purged–CD34+ cell dose infused at the time of
autografting was 3.1 × 106/kg (range, 2.1 × 106 to 9.9 ×
106/kg). Neutrophil recovery (ANC >500/µL) and platelet
recovery (>20,000/µL) occurred a median of 13 days (range,
10-16 days) and 16 days (range, 12-116 days) after AHCT,
respectively. One patient died of progressive disease before
platelet recovery. The median number of platelet and RBC
transfusions was 2 (range, 1-5) and 13 (range, 7-28), respec-
tively. One patient continued to receive intermittent
platelet and RBC transfusions at the time of lymphoma
relapse and death. The median number of days between the
beginning of phase 1 and the beginning of phase 4 was 65
(range, 55-83 days).
Toxicity
The short- and long-term toxicities identified during
the HDSC regimen in the 11 patients completing all
4 phases are summarized in Table 2. There were 6 hospital
readmissions in 4 patients, all related to infectious complica-
tions after phase 1 (n = 2) and 4 (n = 4). Four of the readmis-
sions were due to episodes of fever during the time of neu-
tropenia without an infectious agent identiﬁed. There were
6 documented infections, including bacteremia with Kleb-
siella pneumoniae, pulmonary Aspergillus, cutaneous Herpes
simplex virus I, and dermatomal Varicella zoster. The episode
of pulmonary aspergillosis was diagnosed by lung wedge
resection and successfully treated with amphotericin and
itraconazole. Severe hemorrhagic cystitis occurred in 3
patients, with the onset after phase 1 (high-dose cyclophos-
phamide). In 1 patient, hemorrhagic cystitis recurred after
each subsequent phase of therapy. The institution of contin-
uous bladder irrigation did not alter the incidence of severe
hemorrhagic cystitis. Cardiomyopathy was diagnosed in 2
patients, 3 months and 19 months posttransplantation. Both
patients had received CHOP chemotherapy before begin-
ning HDSC/AHCT, 8 cycles in the patient with the earlier
onset and 2 cycles in the patient with the later onset of con-
gestive heart failure. The patient who had received 8 cycles
of CHOP chemotherapy had a left ventricular ejection frac-
tion of 50% but evidence of left ventricular enlargment by
multiple-gated acquisition (MUGA) scan before transplan-
tation. Planned posttransplantation consolidative radiother-
apy to the right axilla and supraclavicular areas was can-
celled in this patient due to clinical congestive heart failure.
The second patient did not undergo cardiac imaging before
HDSC/AHCT. Both patients currently have clinically com-
pensated congestive heart failure while on cardiac medica-
tions. Prolonged cytopenias occurred in 2 patients. One
patient had anemia and thrombocytopenia with subsequent
lymphoma relapse at 10 months and death at 19 months
posttransplantation. The remaining patient had continued
mild pancytopenias but without blood product or growth
factor support within 1 month of AHCT. The cytogenetic
abnormality of inversion of chromosome 16 was identiﬁed
on bone marrow evaluation 6 months after AHCT. The
patient was alive without recurrent lymphoma or progres-
sive hematologic disease at 2.6 years of follow-up. There
were no treatment-related deaths in the 11 patients who
received transplants on this protocol.
Survival
An intention-to-treat analysis is illustrated in Figure 3.
Four of the 9 nonevaluable patients received HCT on an
alternate protocol. One patient received AHCT with the
preparative regimen of BCNU, etoposide, and cyclophos-
phamide and peripheral blood progenitor cells as the auto-
graft because of persistent fevers during neutropenia after
phase 1 of HDSC. A second and third patient received the
above preparative regimen but with bone marrow as the auto-
graft because of poor mobilization after phase 1 of HDSC.
One of these patients also had persistent hemorrhagic cystitis
and fevers after phase 1. The fourth patient had progressive
disease after phase 1 of HDSC and proceeded to matched
sibling donor bone marrow transplantation (BMT). Two of
the 4 were alive, 1 disease-free without additional therapy at
37 months after ABMT and 1 disease-free having relapsed
after ABMT with a subsequent response to salvage therapy
21 months after phase 1 of HDSC. The patient receiving the
matched sibling donor BMT died of veno-occlusive disease of
the liver on day 25 post-BMT without documented NHL,
and the patient who underwent autologous peripheral blood
progenitor cell transplantation died of progressive lymphoma
189 days after autografting. At a median follow-up of
2.6 years in the intention-to-treat analysis, the 2-year EFS
was 35%, relapse rate 50%, and OS 55% (Figure 4). The
median follow-up of the 11 patients who completed the
Table 3. Characteristics of High-Dose Sequential Chemotherapy/Autologous
Hematopoietic Cell Transplantation (HDSC/AHCT) Patients Compared
With Patients Receiving Standard High-Dose Therapy (HDT)*
HDSC/AHCT Standard HDT
n 11 80
Histologic subtype
Diffuse large cell 8 29
Follicular, diffuse mixed 0 10
Follicular, large cell 0 4
Immunoblastic 0 4
Anaplastic large cell 0 5
Mantle cell 0 10
Small noncleaved 2 1
T-cell–rich B-cell 1 0
Lymphoblastic 0 2
Peripheral T-cell 0 3
Follicular, small cleaved 0 11
Composite 0 1
Remission status
Responsive high-risk 1 4
CR2 1 17
Beyond CR2 0 3
Responsive Relapse 5 32
PR1 1 3
PR2 2 25
PR>2 — 4
PR3 1 —
Untested relapse 2 1
Induction failure 2 23
IF1 0 4
IF2 2 18
IF3 0 1
*CR indicates complete remission; PR, partial remission; IF, induc-
tion failure.
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planned treatment was 2.8 years, with a 2-year EFS of 55%,
relapse rate 45%, and OS 70% (Figure 5).
DISCUSSION
HDSC/AHCT did not improve survival in the relapsed/
refractory NHL patients beyond what is expected from the
conventional HDT/AHCT approach. During the same time
period as this HDSC/AHCT clinical trial, a cohort of
80 adult patients with chemosensitive relapsed or refractory
NHL were autografted at Stanford Hospital with our stan-
dard AHCT protocol, which is a preparative regimen of frac-
tionated total body irradiation or BCNU with etoposide and
cyclophosphamide [8]. Table 3 summarizes the NHL histol-
ogy and remission status of the standard AHCT and
HDSC/AHCT patients. The majority of the standard
AHCT patients (60 of 80) received 2 prior regimens. CHOP
was the most common induction regimen, and DHAP or
ESHAP was the most common salvage regimen, similar to
the prior chemotherapy history of the HDSC/AHCT
patients. The estimated 2-year EFS, relapse rate, and OS
were 52%, 46%, and 70%, respectively (Figure 6). 
Our HDSC/AHCT survival results have been attained
despite the encouraging outcome from 2 clinical trials using
HDSC/AHCT as initial therapy in newly diagnosed NHL
patients [2,9]. Gianni et al. [2] randomized high-risk, diffuse
large B-cell NHL patients to HDSC/AHCT (48 patients)
versus MACOP-B (methotrexate, doxorubicin, cyclophos-
phamide, vincristine, prednisone, bleomycin) (50 patients).
High-risk features were deﬁned as a bulky mass >10 cm or
stage III to IV disease. At a median follow-up of 55 months,
freedom from progression (84% versus 49%, P < .001) and
EFS (76% versus 49%, P = .004) were signiﬁcantly improved
after HDSC/AHCT compared with MACOP-B. Although
OS was increased after HDSC/AHCT (81% versus 55%) it
was not statistically signiﬁcant (P = .09). The second study
was a phase 2 trial with NHL patients prospectively iden-
tified within the high-/intermediate- and high-risk groups
of the IPI [10]. Thirty-two patients (28 intermediate-
grade and 4 high-grade NHL) received HDSC/AHCT.
The OS and RFS at 18 months for all patients were 78%
and 67%, respectively.
The Parma trial has established the survival advantage
for patients with chemoresponsive, recurrent, intermediate-
grade NHL following HDT/AHCT compared with contin-
ued conventional salvage therapy [1]. The initial results
reported a 5-year DFS of 46% and a 5-year OS of 53%. A
recent update reported an 8-year DFS of 35% and OS of
47% [11]. In our current study, the 2-year DFS and OS in
the 11 evaluable patients were similar to the 5-year Parma
trial results. The intention-to-treat analysis was disappoint-
ing, with a 2-year DFS of 35% and an OS of 55%. These
survival data were also consistent with the Parma trial, in
that one half of originally enrolled patients were not
randomized because of chemoresistant disease. In our expe-
rience, approximately 50% of patients with NHL who pres-
ent for our conventional AHCT protocol do not proceed to
transplantation, more than half of them because of refrac-
tory or progressive disease. It is well known that patients
with unresponsive disease have minimal or no chance of
long-term survival following conventional HDT/AHCT
[12]. Before the completion of the Parma trial, a retrospec-
tive review of HDT/AHCT in relapsed/refractory NHL
reported 0%, 14%, and 36% 3-year DFS in refractory,
Figure 6. Kaplan-Meier survival curves of 80 patients with recurrent/refractory non-Hodgkin’s lymphoma receiving standard autologous hemato-
poietic cell transplantation at Stanford University from January 1996 through December 1997 (the same time period during which the current study
population was treated). indicates overall survival; , event-free survival; , relapse rate.
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resistant, and sensitive relapsed disease, respectively. Vose et
al. [13] also found chemosensitivity to be a prognostic vari-
able upon retrospective review of HDT/AHCT for NHL
among patients in the American Bone Marrow Transplanta-
tion Registry. Three-year OS was 19% and 48% for patients
with resistant and chemosensitive disease, respectively. Five
of our 20 enrolled patients failed after the first or second
phase of HDSC because of progressive disease. Despite the
use of high-dose, nonmyeloablative therapy early after fail-
ure of induction or salvage therapy, the refractory patients
remained resistant to disease control.
As mentioned above, the patients completing all phases of
HDSC/AHCT enjoyed a survival similar to that of chemore-
sponsive patients receiving conventional HDT/ AHCT.
There were, however, signiﬁcant reversible and irreversible
morbidities associated with the HDSC/AHCT regimen.
Most notably, 2 of the 11 patients who had undergone trans-
plantation developed congestive heart failure that required
continued medical therapy. Both of them had normal cardiac
function before HDSC. Grade II or greater hemorrhagic cys-
titis occurred in one third of all patients (6 of 20) after phase 1
(high-dose cyclophosphamide). Prophylactic measures
included hyperhydration with forced diuresis and, later, con-
tinuous bladder irrigation. Our higher incidence of hemor-
rhagic cystitis may have been related to altering the original
protocol so that MESNA (sodium 2-mercapto-ethane
sulphonate) was administered with the high-dose cyclophos-
phamide [2,9]. The incidence of grade II or greater hemor-
rhagic cystitis with our standard AHCT protocol has been
approximately 15% (L.J.J., K.S.-G., W.W.H., R.S.N., N.J.
Chao, G.D. Long, K.G.B., S.J.H., unpublished data). Postau-
tografting cytopenias occurred in 2 of the patients who
underwent transplantation, with 1 suffering relapsed NHL
before hematologic recovery. The second patient continues to
have mild leukopenia, thrombocytopenia, and normocytic
anemia; a cytogenetic abnormality (inversion of chromosome
16) was identiﬁed within 1 year of transplantation. No patient
has been diagnosed with frank myelodysplasia or acute
leukemia, although the median follow-up remains short. The
incidences of the regimen-related toxicities such as mucositis,
infection, fever of unknown origin, and renal and hepatic
insufﬁciency were not markedly different from those expected
after conventional HDT/ AHCT. Interestingly, the TRM in
the 11 transplantation patients was 0% in our series com-
pared with 6% and 8% in the 2 other HDSC/AHCT studies
[2,9], in which the causes of death were sepsis and veno-
occlusive disease. The use of fractionated total body irradia-
tion rather than mitoxantrone in the ﬁrst 30 of 48 patients in
the Italian trial may explain a portion of their early deaths.
In conclusion, this pilot trial of HDSC/AHCT in the
relapsed/refractory NHL patient resulted in a survival rate
similar to the conventional HDT/AHCT approach but with
substantially more treatment-related morbidity. In addition,
this HDSC/AHCT regimen did not rescue the patient with
refractory or marginally responsive NHL. We chose to ter-
minate this trial because of the untoward toxicities without
the expected improved survival. Patients with refractory or
marginally responsive NHL continue to represent a major
challenge to clinicians, and novel therapies are needed.
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